{"DataElement":{"publicId":"2469148","version":"1","preferredName":"Non-protocol Therapy 5 Alpha-Reductase Inhibitor Administered Reason","preferredDefinition":"an explanation for use of a substance to inhibit 5-alpha-reductase, an enzyme metabolizing testosterone to dihydrotestosterone, for therapeutic purposes not specified for a clinical trial.","longName":"NP_TX_5AR_IN_ADM_RSN","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2468985","version":"1","preferredName":"Non-protocol Therapy 5 Alpha-Reductase Inhibitor Administered","preferredDefinition":"related to the use of substances that inhibit 5-alpha-reductase, an enzyme that metabolizes testosterone to dihydrotestosterone, for therapeutic purposes not specified for a clinical trial.","longName":"NPR_TX_5ARED_INH_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2206588","version":"1","preferredName":"Non-Protocol Therapy","preferredDefinition":"Treatment not specified in a protocol.:An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","longName":"C25590:C15368","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Non-Protocol","conceptCode":"C25590","definition":"Treatment not specified in a protocol.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Therapy","conceptCode":"C15368","definition":"An action or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"F37D0428-FB27-6787-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-03-29","endDate":null,"createdBy":"SBR","dateCreated":"2005-03-29","modifiedBy":"ONEDATA","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2468983","version":"1","preferredName":"5 Alpha-Reductase Inhibitor Administered","preferredDefinition":"Substances that inhibit 5-alpha-Reductase, an enzyme that metabolizes testosterone to dihydrotestosterone, and can reduce prostate size.:Given.","longName":"C2319:C25382","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"5 Alpha-Reductase Inhibitor","conceptCode":"C2319","definition":"Any substance that inhibits steroid 5-alpha-reductase, an enzyme that converts testosterone into dihydrotestosterone (DHT). Since DHT has three times greater affinity for androgen receptors than testosterone, inhibition of 5-alpha-reductase results in a strong reduction in the androgenic effects of testosterone.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10A0CF90-FC4B-7441-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-04","endDate":null,"createdBy":"PWEST","dateCreated":"2006-04-04","modifiedBy":"ONEDATA","dateModified":"2006-04-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10A0DACD-E6DD-0027-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-04","endDate":null,"createdBy":"PWEST","dateCreated":"2006-04-04","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2469147","version":"1","preferredName":"Non-Protocol Therapy Administered Reason","preferredDefinition":"an explanation for used of any substance given for therapeutic purposes not specified for a clinical trial.","longName":"NPROT_TX_ADM_RSN","context":"CTEP","contextVersion":"2.31","type":"Non-enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2184326","version":"1","preferredName":"Reason","preferredDefinition":"An explanation of the cause of some phenomenon or action.","longName":"Reason","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Reason","conceptCode":"C25638","definition":"An explanation of the cause of some phenomenon or action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB6C8AC6-1F62-3E75-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"SBREXT","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-04-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"10B046AB-897B-02D9-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-05","endDate":null,"createdBy":"PWEST","dateCreated":"2006-04-05","modifiedBy":"PWEST","dateModified":"2006-04-05","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[],"AlternateNames":[],"ReferenceDocuments":[{"name":"Reason for use","type":"Preferred Question Text","description":"Reason for use","url":null,"context":"CTEP"}],"origin":"NCIC CRF:National Cancer Institute of Canada Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"10B055DB-E482-025D-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-04-05","endDate":null,"createdBy":"PWEST","dateCreated":"2006-04-05","modifiedBy":"CAMPBELB","dateModified":"2011-11-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}